ResearcherTaizhou Central HospitalActive in the last 2 years

Jie Zhu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-9836-8035; OpenAlex author ID A5044911914. Sources: OpenAlex.

Their work

Papers: 2 (first author 0, last author 1)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 4

Papers, trials and grants by year

2021: 1 paper · 2022: none · 2023: none · 2024: 1 paper

Papers 2

Downregulation of miR-503-5p Promotes the Development of Pancreatic Cancer by Targeting Cyclin E2. Last author DOI 10.1615/critrevimmunol.2024051136 ↗
circRNA circ_102049 Implicates in Pancreatic Ductal Adenocarcinoma Progression through Activating CD80 by Targeting miR-455-3p. Co-author DOI 10.1155/2021/8819990 ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Fei Li · 1 shared paper, 2024 · strength 0.26
- Paper Downregulation of miR-503-5p Promotes the Development of Pancreatic Cancer by Targeting Cyclin E2. DOI 10.1615/critrevimmunol.2024051136 ↗
Hao Jiang · 1 shared paper, 2024 · strength 0.26
- Paper Downregulation of miR-503-5p Promotes the Development of Pancreatic Cancer by Targeting Cyclin E2. DOI 10.1615/critrevimmunol.2024051136 ↗
Jiajia Xu · 1 shared paper, 2021 · strength 0.15
- Paper circRNA circ_102049 Implicates in Pancreatic Ductal Adenocarcinoma Progression through Activating CD80 by Targeting miR… DOI 10.1155/2021/8819990 ↗
Hai-Rong Shu · 1 shared paper, 2021 · strength 0.15
- Paper circRNA circ_102049 Implicates in Pancreatic Ductal Adenocarcinoma Progression through Activating CD80 by Targeting miR… DOI 10.1155/2021/8819990 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.